Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 12/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209662 | 0.92 | YES1 (0.44) | KDRPDGFRAYES1METCYP3A4 | |
| SCHEMBL3711136 | 0.87 | MET (0.43) | YES1METCYP3A4KCNH2ACP1 | |
| SCHEMBL3694325 | 0.85 | FGFR2 (0.40) | KDRPDGFRAYES1METCYP3A4 | |
| SCHEMBL3698351 | 0.77 | PIK3CA (0.41) | KDRPDGFRAYES1METABL1 | |
| SCHEMBL3704091 | 0.77 | YES1 (0.48) | KDRPDGFRAYES1METCYP3A4 | |
| SCHEMBL15663626 | 0.75 | KDR (0.39) | KDRPDGFRAYES1METCYP3A4 | |
| SCHEMBL15663295 | 0.75 | MAPT (0.55) | KDRPDGFRAYES1CYP3A4 | |
| SCHEMBL2209181 | 0.74 | KDR (0.41) | KDRPDGFRAYES1METCYP3A4 | |
| SCHEMBL15663410 | 0.74 | MAPT (0.45) | KDRPDGFRACYP3A4 | |
| SCHEMBL2209534 | 0.74 | MAPT (0.48) | KDRYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885YES1 295/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885YES1 295/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885YES1 295/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | KDR 644/4885PDGFRA 1102/4885YES1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.